secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001193125-25-039299
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soleno reports FY2024 net loss of $175.9M; cash $318.6M; PDUFA for DCCR on March 27, 2025
--------------------------------------------------------------------------------

- Net loss $(175.9)M ($4.38/share) vs $(39.0)M in 2023; R&D expense $78.6M, G&A $105.9M.
- Cash, cash equivalents and marketable securities $318.6M at Dec 31, 2024; used $69.1M in operations.
- NDA for DCCR (PWS) under FDA Priority Review with PDUFA target March 27, 2025.
- Entered loan agreement with Oxford for up to $200M ($50M upfront); completed $158.7M public offering in May 2024.
- Appointed Dawn Carter Bir to Board; Matthew Pauls as Lead Independent Director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312525039299/0001193125-25-039299-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312525039299/d882131d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-039299

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer